Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.

Wysham CH, Rosenstock J, Vetter ML, Wang H, Hardy E, Iqbal N

BMJ open diabetes research & care1 Oct 2020Cited by 4 (Europe PMC)

PMID33037036PMCIDPMC7549491DOI10.1136/bmjdrc-2019-000773PepBankPUB-33037036

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In T2D, continued weekly exenatide reduced A1C from baseline at week 52.
In plain wordsIn T2D, continued weekly exenatide reduced A1C from baseline at week 52.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C with continued weekly treatment
Study
n = 197
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg · 52 weeksAs given in this study (human).
Measurements
A1C change from baseline
−1.3%
continued exenatide QWS-AI, week 52
Source sentences
Summary
Patients who continued exenatide QWS-AI treatment for 52 weeks showed clinically relevant A1C reductions (mean A1C change from baseline of -1.3% at week 52).
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Report a problemFND-3303703603
02HumanNon-randomized trialEfficacy outcome
In T2D, patients who continued weekly exenatide maintained their earlier weight reductions at week 52.
In plain wordsIn T2D, patients who continued weekly exenatide kept their weight reductions from baseline at week 52.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight reduction with continued weekly treatment
Study
n = 197
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mgAs given in this study (human).
Source sentences
Summary
Body-weight reductions achieved through week 28 were sustained at week 52 in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Report a problemFND-3303703605
03HumanNon-randomized trialSafety outcome
In T2D, continued weekly exenatide produced no unexpected safety concerns or safety profile changes.
In plain wordsIn T2D, continued weekly exenatide produced no unexpected safety concerns or safety profile changes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSafety profile with continued weekly treatment
Study
n = 197
Outcome group
Adverse events · Whole body
Studied dose
2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
There were no unexpected safety concerns or changes in the safety profile among patients who switched from exenatide two times per day to exenatide QWS-AI or those who continued exenatide QWS-AI treatment for 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Report a problemFND-3303703607
04HumanNon-randomized trialEfficacy outcome
In T2D, switching to weekly exenatide produced further A1C reductions from weeks 28-52.
In plain wordsIn T2D, switching to weekly exenatide further reduced A1C from weeks 28-52.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C after switching
Study
n = 118
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mgAs given in this study (human).
Measurements
A1C change from baseline
−1.4%
switched to exenatide QWS-AI, week 52
Additional A1C reduction
≈ 0.5%
switched to exenatide QWS-AI, weeks 28-52
Source sentences
Summary
From weeks 28-52, patients who switched from exenatide two times per day to exenatide QWS-AI had additional A1C reductions of approximately 0.5% (mean A1C change from baseline of -1.4% at week 52) and further reductions from baseline in FPG.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Report a problemFND-3303703601
05HumanNon-randomized trialEfficacy outcome
In T2D, switching to weekly exenatide produced further FPG reductions from baseline.
In plain wordsIn T2D, switching to weekly exenatide further reduced fasting blood sugar from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFPG after switching
Study
n = 118
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mgAs given in this study (human).
Source sentences
Summary
From weeks 28-52, patients who switched from exenatide two times per day to exenatide QWS-AI had additional A1C reductions of approximately 0.5% (mean A1C change from baseline of -1.4% at week 52) and further reductions from baseline in FPG.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Report a problemFND-3303703602
06HumanNon-randomized trialEfficacy outcome
In T2D, patients who switched to weekly exenatide maintained their earlier weight reductions at week 52.
In plain wordsIn T2D, patients who switched to weekly exenatide kept their weight reductions from baseline at week 52.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight reduction after switching
Study
n = 118
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mgAs given in this study (human).
Source sentences
Summary
Body-weight reductions achieved through week 28 were sustained at week 52 in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Report a problemFND-3303703604
07HumanNon-randomized trialSafety outcome
In T2D, switching to weekly exenatide produced no unexpected safety concerns or safety profile changes.
In plain wordsIn T2D, switching to weekly exenatide produced no unexpected safety concerns or safety profile changes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSafety profile after switching
Study
n = 118
Outcome group
Adverse events · Whole body
Studied dose
2 mgAs given in this study (human).
Source sentences
Summary
There were no unexpected safety concerns or changes in the safety profile among patients who switched from exenatide two times per day to exenatide QWS-AI or those who continued exenatide QWS-AI treatment for 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase III open-label study, adults with type 2 diabetes were randomized to receive exenatide QWS-AI (2 mg) or exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg) for 28 weeks.
Summary · context
During a subsequent non-randomized 24-week extension, patients who received exenatide two times per day were switched to exenatide QWS-AI and those randomized to exenatide QWS-AI continued this treatment.
Report a problemFND-3303703606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01652716

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

AstraZenecan = 377Jan 2013 to Aug 2014

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 3 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.